Search
Influenza A virus A/Washington/19/2020 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB16727ApprovedWithdrawnA seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. … Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3.
Categories: Inactivated Influenza A Virus VaccineSynonyms: Influenza A virus A/Washington/19/2020 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)Lirentelimab
go.drugbank.com/drugs/DB16728InvestigationalLirentelimab is under investigation in clinical trial NCT04856891 (A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis).
Favezelimab
go.drugbank.com/drugs/DB16729InvestigationalFavezelimab is under investigation in clinical trial NCT04626479 (Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A
Adlinacogene civaparvovec
go.drugbank.com/drugs/DB16788InvestigationalIt uses proprietary zinc finger nuclease (ZFN) genome editing to insert into the DNA of liver cells a copy of the F9 gene, which controls the production of Factor IX.
Lixmabegagene relduparvovec
go.drugbank.com/drugs/DB16816InvestigationalLixmabegagene relduparvovec, formerly known as LYS-GM101, is a recombinant adeno-associated virus vector serotype rh.10 (AAVrh.10) carrying the human β-galactosidase gene (GBL1).
LetibotulinumtoxinA
go.drugbank.com/drugs/DB16820Approved[L42330] It is a 900 kDa multimeric complex comprising a 150 kDa toxin, a 130 kDa non-toxic non-haemagglutinating protein, and various other haemagglutinins. … [A249920] LetibotulinumtoxinA is a type A botulinum neurotoxin produced from fermentation of _Clostridium botulinum_ strain CBFC26.
Categories: Botulinum Toxins, Type ASynonyms: BoNT/A-DSRepotrectinib
go.drugbank.com/drugs/DB16826ApprovedInvestigationalRepotrectinib is a next-generation tyrosine kinase inhibitor (TKI) specifically designed to address resistance in the treatment of non-small cell lung cancer (NSCLC), specifically due to mutations in the … [A262056] Repotrectinib possesses a compact macrocyclic structure that both limits adverse interactions with resistance mutation hotspots and targets mutations in the solvent-front region.
Synonyms: (3R,6S,)-45-FLUORO-3,6-DIMETHYL-5-OXA-2,8-DIAZA-1(5,3)-PYRAZOLO(1,5-A)PYRIMIDINA-4(1,2)-BENZENANONAPHAN-9-ONEOlprinone
go.drugbank.com/drugs/DB16847InvestigationalCategories: Compounds used in a research, industrial, or household settingRhodamine B
go.drugbank.com/drugs/DB16853ExperimentalCategories: Compounds used in a research, industrial, or household settingButylated hydroxytoluene
go.drugbank.com/drugs/DB16863InvestigationalCategories: Compounds used in a research, industrial, or household setting